VNP2000 9, a genetically modified strain of Salmonella typhii?Wrium with deletions in the msbB and purl loci, exhibited antitumor activities when given systemically to tumor-bearing mice. VNP2000 9 inhibited the growth of subcutaneously implanted B16F10 murine melanoma, and the human tumor xenografts Lox, DLD-1, A549, WiDr, HTB177, and MDA MB-231. A single intravenous injection of VNP20009 , at doses ranging from 1 x Hf to 3 x 106 cfulrnouse, produced tumor growth inhibitions of 57-95%. Tumor volume doubling time, another indicator for tumor growth inhibition, also significantly increased in mice treated with VNP2000 9. Using mice with immune system deficiencies, we also demon· strated that the antitumor effects of VNP20009 did not depend on the presence ofT and B cells. In addition, VNP20009 , given intravenously, inhibited the growth of lung metastases in mice. Only live bacteria showed the antitumor effect.
described an abscess in a pheochromocytoma con taining 90 cc of thick, yellow pus encapsulated by a thin sphere consisting of a few layers of tumor cells. The bacteria were later identified as S. typhimurium.
The use of bacterial products for cancer treatment dates back to the early 1900s. William B. Coley, who was then a surgeon at Memorial Hospital, now Memo rial Sloan-Kettering Cancer Center, observed that pa· tients with sarcoma responded better after surgery if they developed severe postoperative infections. Coley later developed a regimen containing bacterial cell wall components for the treatment of cancer (7) . The grain positive bacterium Clostridiwn was evaluated as an anti· cancer agent in clinical trials in the 1970s. Although in many cases Clostridiwn was recovered from tumors and oncolysis was observed, these clinical trials were subse quently discontinued because they failed to produce clinical benefits to patients (8) . Bacille Calmette-Guerin (BCG2), another viable bacterium, is being used for the treatment of superficial bladder carcinoma in humans. BCG, an attenuated, avirulent strain of Mycobacterium bovis, is administered by urethral catheterization at peri odic intervals for up to 24 months. In patients with blad der cancer, BCG treannent achieves complete responses in greater than 60% of the patients (9) .
These reports suggest that bacteria could serve as anticancer agents if their virulence were controlled. S. typhimurium, if attenuated, can be safely administered to animals to retard tumor growth in murine tumor mod els. A virulent strains of Salmonella have been developed as vaccines for the prevention of bacterial infections (10, 11) . A viable S. typhi vaccine, Ty2la, has been ap proved for the prevention of typhoid fever in humans (12) . In addition to serving as vaccines against Salmo nellosis, attenuated strains of Salmonella have been used for expressing and delivering heterologous proteins to the immune system. This approach may eventually be developed for combating infections and cancer (13, 14) . Using an aro4-mutant SL3225, Eisenstein et al. We report here that VNP20009, an attenuated strain of S. typhimurium with deletions in the msbB and purl loci, suppresses the growth of subcutaneously implanted tumors and lung metastases. We also show that the anti tumor effects of VNP20009 do not depend on the pres- 
MATERIALS AND METHODS

Cell Culture Conditions
All cell lines were maintained at 37 ± 2°C in a hu midified atmosphere containing 5% C02• B16Fl0 mu rine melanoma, DLD-1 human colon carcinoma, A549 human lung carcinoma cells, HTB 177 human lung carci noma cells, Lox human melanoma, and MDA-MB-231 human breast carcinoma cells were culrured in DuJbec co's modified Eagle's medium supplemented with 10% fetal bovine serum. WiDr human colon carcinoma cells were maintained in Eagle's minimum essential medium, containing Earle's salts, and supplemented with both nonessential amino acids and 1 0% fetal bovine serum. VNP20009 was grown as a liquid culture to an OD600 = 0.8 by suspending a single colony into 25 ml of Luria Bertani (LB) broth. The suspension was diluted in PBS before use, based on 1 OD = 1 x 109 colony forming unit (cfu)/ml. Solid tumors were staged for 6-24 days prior to bacterial inoculation. A 0.2-ml bolus of the PBS diluted bacterial suspension was administered N via the lateral tail vein. Each mouse received approxi mately 1 x 104 to 3 x 106 cfu of VNP20009. Mice bearing lung me tastases were treated with a 0.2-ml bolus of live VNP20009 (containing 2 x 106 cfu) or dead VNP20009 (containing 2 x 10 8 cfu) 5 days after tumor inoculation. Actual doses were determined by plating the dosing so lution on LB agar plates, and colonies were enumerated after overnight incubation at 37°C. Cyclophosphamide (Sigma, Milwaukee, WI), used as a positive control, was given 1P at a dosing schedule of 200 mglkg, once week ly for 3 weeks. In some experiments, SCID mice receiv ing VNP20009 also received oral ciprofloxacin, 100 mgl kg, twice daily for 5 days. In comparison studies, killed VNP20009 was prepared by autoclaving the bacteria for 20 min, and lack of viability was confirmed by plating.
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Tumor Measuremems
Tumor size was determined from measurements ob tained with electronic calipers along three axes: length (L), width (W), and height (H). The volume of the tumor was calculated using the following formula: tumor vol ume = (L x W x H)/2. The mean tumor volume and standard deviation of all animals comprising each group were determined. Tumor volume of individual animals from control and treated groups at the end of experiment was also analyzed with the Student's t-test. Lungs with metastases taken from mice were weighed and photo graphed.
Histopathological Studies
To analyze mechanisms involved in the observed an titumor effects, Bl6F10 tumors that were treated with PBS or VNP20009 were removed from mice 3-11 days after treatment and fixed with 4% buffered formalin. The specimens were embedded in paraffin, and 6-�m thick sections were stained sequentially with H&E for microscopic examination.
Animal Care
All animals were treated, fed, housed, and handled according to guidelines established by the National Re search Council. The animals used in this study were ob tained from Charles River Laboratories (Wilmington, MA). Animals selected in this study were as uniform in age and weight as possible. They were approximately 8-10 weeks of age, and their body weights ranged from 18 to 22 g. Animals were housed in plastic cages with stainless steel covers and were identified by an ear tag. Five mice were housed in each cage. Mouse Chow food was available ad libitum via food hoppers. Tap water was provided in glass bottles ad libitum. All animals were kept in a well-ventilated room where a 12-h light/ 12-h dark photoperiod was maintained. Room tempera ture was maintained at 72 ± 2°F. At the end of the study, animals were euthanized in a dry ice-containing chamber.
RESULTS
The ability of VNP20009 to inhibit tumor growth was examined over a dose range of 1 x l 04 to 1 x 10 6 cfu/mouse in the SC B16Fl0 melanoma model. Mice were administered VNP20009 IV on day 7, and tumor volwnes were measured on days 10, 13, 17, and 20 ( Fig. 1) . The differences observed between individual groups were deemed significant when analyzed by the Student's two-tailed t-test. All doses were found to give significant antitumor activity (P < 0.01 ). A single dose of VNP20009 at 1 x 105 cfu/mouse produced responses equivalent to, or better than, the antitumor drug cyclo phosphamide, which was given three times during the course of treatment. Figure 2 demonstrates that VNP20009 inhibited the growth of B16FIO melanoma implanted into immuno competent C57BU6 ( Fig. 2A) , athymic nude (Fig. 2B) , or SCID mice (Fig. 2C) . A single injection of VNP20009 produced a tumor growth inhibition of 85% or more re- gardless of strain of mice used. SCID mice were sensi tive to VNP20009 treannent, and started dying 7 days after bacterial injection when no antibiotics were given.
No mortality or weight loss was noted in C57B/6 or athymic nude mice treated with VNP20009 . Significant antitumor activities (P < 0.01, t-test) were recorded in all the treated groups. Athymic nude mice bearing A549, WiDr, or DLD-1 tumors were treated with VNP20009 at a dose of 2 x 106 cfu/mouse on day 6 (A549), day 8 (WiDr), or day 13 (DLD-1). A single injection of VNP20009 caused sig nificant and sustained tumor growth inhibitions of 54%, 65%, and 74% for A549, WiDr, and DLD-1, respec tively (Fig. 3) . MDA-MB-231 tumors grew in nude mice and were staged for 24 days before dosing. Similar re sults were obtained, with a single dose of VNP20009 inhibiting the growth of MDA-MB-231 tumors more than 70%. HTB 177 lung carcinoma staged to 11 days after implantation into SCID mice was treated with a dose of 1 x 106 cfu/mouse. This dose of VNP20009 pro duced a 94% tumor growth inhibition at the 10-day in terval (Fig. 3E) . The experiment was terminated on day 20 because of the death of animals caused by bacterial infection. VNP20009 inhibited tumor growth regardless of size of tumors at the rime of treannent (0.05-0.3 g). It was equally efficacious in inhibiting fast (B16F10, Lox) or slow growing (MDA-MB-231, DLD-1) tumors.
In another experiment using SCID mice bearing Lox human melanoma, the antibiotic ciprofloxacin was given to mice receiving VNP20009. All the SCID mice treated with VNP20009 alone died before day 15 (i.e., 10 days after VNP20009 dosing). In contrast, all the mice sur vived that received ciprofloxacin 4 days after VNP20009 treatment. In addition, a very significant delay of tumor growth was observed in animals receiving VNP20009 alone or VNP20009 plus ciprofloxacin (Fig. 3F) . Twnor volume doubling time in treated animals was significandy increased compared with vehicle-treated controls.
VNP20009, at a dose of 2 x 106 cfu/mouse injected IV, inhibited the growth of lung metastases compared with untreated controls (Fig. 4) . Similar experiments carried out in athymic nude, SCID, and beige mice produced comparable results. In addition, only viable bacteria inhibited the growth of lung metastases. When VNP20009 was heat inactivated, even if given at a higher amount, no antitumnor effects were observed (Fig. 5) .
Tumor sections were prepared from untreated mice and mice treated with VNP20009 for various days. At least three tumors for each time point and 20 slides from each tumor were examined for the presence or absence of necrosis and infiltrating cells. Sections taken from tu mors treated with VNP20009 revealed a massive infil tration of immune cells accompanied with an extensive necrosis in the central part of the tumors. Significant tumor necrosis (over 70% surface of tumor tissue) was found in mice treated with VNP20009 for 7 days, com pared with PBS-treated control mice (Fig. 6} . The dead and dying tumor cells were stained with bright red color, characterized with an increase in cell size and the disin tegration of the nuclei. Infiltrating cells formed a zone surrounding the necrotic center of the tumor (Fig. 6A) . Most of infiltrating cells, at higher magnification, were shown to be neutrophils with horseshoe-shaped nuclei (Fig. 6B) . In contrast, tumors obtained from mice treated with PBS (Fig. 6C) revealed a relatively low level of necrosis at the center (less than 5% surface of tumor section) and with only a few infiltrating immune cells (Fig. 6D) .
DISCUSSION
In previous studies, we have demonstrated that a sin gle dose of YS1629, a msbB knockout mutant, is highly effective in inhibiting the growth of B16 murine mela- cfulmouse was injected IV into tumor-bearing mice 7-9 days after tumor implantation. **P < 0.01.
LUOETAL.
noma (15).
In this report, we further demonstrate that a single dose of VNP20009, a tetracycline-sensitive, msbB and purl knockout mutant, is also capable of suppressing tumor growth in human tumor xenograft models repre senting melanoma and lung, breast, and colon cancer. Similar to previous observations with B16F10 mela noma, a single dose of VNP20009 inhibited rumor growth, consistent with an ability of VNP20009 to persist within tumor xenografts (17) . Only a slight dose-response cor relation was observed between VNP20009 levels and tu mor inhibition in Bl6Fl0 melanoma, because VNP200 09 replicates within the tumor, producing a greater than ex pected potency at lower doses (18) . The antitumor activ ity of VNP20009, at the dose of 1 x 105 cfulmouse, is superior to that induced by the antitumor drug cyclo phosphamide, which has been given at the optimal dos ing schedule for this tumor. Toxicology study of the VNP20009 revealed that SCID mice were approximately 5-to 50-fold less toler ant compared with immune-competent mice (data not shown), which was consistent with the enhanced sensi tivity of SCID mice to Salmonella infection previously reported with other attenuated Salmonella strains (19) . Athymic CD-1 nude mice and immune-competent CD-1 mice had similar LD50 values for VNP20009 (data not shown). These data suggest that B cells may be involved in the clearance of VNP20009. Without receiving treat ment of ciprofloxacin, SCID mice succumbed to bacte rial infections and began to die 1 0 days after VNP20009 dosing. Nevertheless, VNP20009-mediated mortality in SCID mice could be completely prevented by antibiotic administration, without affecting the antitumor efficacy. Number of bacteria in both liver and tumor decreased by 90% to 99% with the current dosing schedule during antibiotic treatment but returned to normal levels a few days after treatment ended (data not shown). Page Clisson et al. (20) reported similar results that ciprofl ox acin could not completely eradicate the persistence of S. typhimurium in liver and spleen. It should also be noted that VNP20009 inhibited tumor growth in immu nocompromised mice with T-cell and B-cell deficien cies. Using an experimental metastasis model, we dem onstrated that the antitumor activity of VNP2000 9 may not require T cells, B cells, and natural killer cells (un published data). Schafer et al. (21) reported that live, attenuated Salmonella was capable of inducing tumorici dal macrophages in C3H/HeJ mice, whereas BCG was not effective in that strain of mice. Our finding that only viable VNP20009 shows antitumor effects suggests that the antitumor mechanism of VNP20009 differs from that ofBCG.
The mechanisms involved in tumor growth inhibition by VNP20009 are not completely understood. It is possi ble that some cell wall components of live S. typhimu rium are cytotoxic to mammalian cells and induce apop tosis in macrophages and granulocytes (22) . Galan and his coworkers suggested that a type m secretion system is responsible for the Salmonella-induced apoptosis in cultured mammali an cells (23) . VNP20009 accumulated at high levels inside the tumor mass, which could induce low levels of cytokines, such as TNF-a in situ that elic- ,.
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Ciprof1oxa�n 1 OOrnpiri. Bidx5 � cfu/mouse 6 to 24 days after tumor implantation. *P < 0.05; **P < 0.01. Unlike Clostridium, which is an obligate anaerobe and colonized only in hypoxic and necrotic areas of tumors, S. typhimurium is a fa£ultativc anaerobe and is dtstrihnted homogeneously throughout the enlire tumor and is accumulated in tumors as small as 0. l g (24) . Clostridium accumulated and exerted its oncolytic cf.· fccts only in largt� tumors (8, 25, 26) antitumor activity has not been evaluated under these conditions. VNP20009 has been atlen uated at least lfLOOO -fo!d compared with the activity (lf the parental wild·-type Salmonella strain in immunocompetent C57BL/6 mice (27) . Our studies suggest that T-ecH-defi cient nudt� mice are nol overlv sensitive to VNP20009.
in con lrast lO studies usmg mi�e with both T-ecH and B ed! deficiency. These results are consistent with a prt�\i ous report dcmonsl.rating that moderalc immunodcticien cy, resulting from sublethal irrad. iation of BALB/c. mice, does not cause an increase in susccptihi!ity to an allenu ated aro4-strain of Salmonella (28) . VNP20009 is wen -· : tolerated in nonhuman primates; the highest nontoxic dose via IV injection is 2.5 x lOg cfulkg (18, 27) . The probability of VNP2000 9 reverting to wild-type bacteria is unlikely, because VNP2000 9 was attenuated by delet ing both the msbB and purl genes from the bacterial genome. Because of its potent inhibitory effect in a wide spectrum of human cumor xcnografts and its relatively nontoxic characteristics in nonhuman primates. VNP20009 is currently being evaluated as a potential antitumor agent in humans. Moreover, VNP20009 preferentially accumulated in tumor tissues, reaching levels as high as l x 109 cfu/g rumor, a concentration 100 0 times higher than that found in liver and other normal tissues (17) . The use of VNP20009 as a tumor-selective vector to deliver cytosine deaminase to tumors is currently being evaluated in human clinical trials (29) .
